The decision affects THR-687, a pan RGD integrin antagonist for the treatment of diabetic macular oedema (DME), and leaves Oxurion with a single clinical-stage candidate – plasma kallikrein ...

THR-149 is one of a pair of drugs Oxurion has in mid-stage testing for DE along with pan-RGD integrin antagonist THR-687, which is in the phase 2 INTEGRAL study in previously-untreated DME patients.

Integrins are very attractive therapeutic targets in oncology. The anti-tumor mechanisms of integrin-targeting drugs have been validated both in vitroand in vivo. Integrin-targeting drugs are ...

KS1767 cells were detached with cold EDTA and re-suspended in MEM containing 1% BSA. αv integrin-binding RGD-4C phage were used as defined ligands. The cell suspension was incubated with RGD-4C ...